Profile data is unavailable for this security.
About the company
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
- Revenue in USD (TTM)16.74m
- Net income in USD-105.46m
- Incorporated2014
- Employees110.00
- LocationStoke Therapeutics Inc45 WIGGINS AVENUEBEDFORD 01730United StatesUSA
- Phone+1 (781) 430-8200
- Fax+1 (302) 531-3150
- Websitehttps://www.stoketherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grail Inc | -100.00bn | -100.00bn | 550.38m | 1.37k | -- | 0.2102 | -- | -- | -- | -- | -- | 77.93 | -- | -- | -- | -- | -- | -47.45 | -- | -48.55 | -- | -- | -- | -5,118.86 | -- | -- | -- | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
| MBX Biosciences Inc | -100.00bn | -100.00bn | 551.72m | 36.00 | -- | 2.03 | -- | -- | -- | -- | -- | 8.13 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
| Kezar Life Sciences Inc | 0.00 | -95.78m | 555.97m | 58.00 | -- | 0.4148 | -- | -- | -13.15 | -13.15 | 0.00 | 18.37 | 0.00 | -- | -- | 0.00 | -46.34 | -32.54 | -50.90 | -34.09 | -- | -- | -- | -4,308.11 | -- | -- | 0.0711 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Savara Inc | 0.00 | -82.94m | 556.05m | 37.00 | -- | 2.78 | -- | -- | -0.4452 | -0.4452 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -39.41 | -36.86 | -41.56 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.1175 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -56.83m | 559.21m | 28.00 | -- | 45.09 | -- | -- | -0.9262 | -0.9262 | 0.00 | 0.1983 | 0.00 | -- | -- | 0.00 | -102.63 | -38.31 | -199.23 | -43.34 | -- | -- | -- | -- | -- | -34.33 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Tourmaline Bio Inc | 0.00 | -48.85m | 582.60m | 44.00 | -- | 1.81 | -- | -- | -1.68 | -1.68 | 0.00 | 12.52 | 0.00 | -- | -- | 0.00 | -20.37 | -- | -21.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Chromadex Corp | 91.67m | 1.49m | 582.80m | 106.00 | 403.06 | 16.88 | 250.56 | 6.36 | 0.0189 | 0.0189 | 1.21 | 0.4521 | 1.67 | 3.05 | 23.51 | 864,792.40 | 2.70 | -42.11 | 4.08 | -65.14 | 61.45 | 59.68 | 1.62 | -30.64 | 2.35 | -- | 0.0004 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Immunome Inc | 10.13m | -305.35m | 586.73m | 55.00 | -- | 2.65 | -- | 57.93 | -6.06 | -6.06 | 0.1889 | 3.56 | 0.0579 | -- | -- | 184,163.60 | -174.46 | -94.54 | -212.48 | -112.66 | -- | -- | -3,014.59 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Mineralys Therapeutics Inc | 0.00 | -153.25m | 590.26m | 28.00 | -- | 2.49 | -- | -- | -3.27 | -3.27 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -56.16 | -- | -61.19 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Stoke Therapeutics Inc | 16.74m | -105.46m | 596.94m | 110.00 | -- | 2.57 | -- | 35.65 | -2.10 | -2.10 | 0.3294 | 4.38 | 0.0628 | -- | 42.55 | 152,209.10 | -39.56 | -31.62 | -46.04 | -33.92 | -- | -- | -629.86 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Altimmune Inc | 52.00k | -103.52m | 597.35m | 59.00 | -- | 4.48 | -- | 11,487.53 | -1.55 | -1.55 | 0.0008 | 1.88 | 0.0003 | -- | 0.0798 | 881.36 | -65.84 | -39.62 | -70.44 | -42.58 | -- | -- | -199,076.90 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Dianthus Therapeutics Inc | 5.37m | -67.09m | 599.93m | 53.00 | -- | 1.76 | -- | 111.80 | -2.49 | -2.49 | 0.1968 | 11.51 | 0.0196 | -- | 3.13 | 101,245.30 | -24.54 | -41.40 | -25.91 | -44.70 | -- | -- | -1,250.32 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -119.87m | 643.35m | 112.00 | -- | 2.35 | -- | -- | -1.81 | -1.81 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -41.59 | -33.92 | -44.71 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
Data as of Nov 22 2024. Currency figures normalised to Stoke Therapeutics Inc's reporting currency: US Dollar USD
66.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Lynx1 Capital Management LPas of 30 Sep 2024 | 5.19m | 9.85% |
| Redmile Group LLCas of 30 Sep 2024 | 4.71m | 8.95% |
| RTW Investments LPas of 30 Sep 2024 | 4.65m | 8.84% |
| Baker Bros. Advisors LPas of 30 Sep 2024 | 4.37m | 8.30% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 4.20m | 7.97% |
| TD Securities (USA) LLCas of 30 Sep 2024 | 3.24m | 6.16% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.66m | 5.04% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.54m | 4.83% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.73m | 3.28% |
| Marshall Wace LLPas of 30 Sep 2024 | 1.67m | 3.17% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
